Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMC

Novel bioengineering strategies for drug delivery systems

Jang Y., Kim A., Moon JJ., Lee JY., Park H.

Animal Study on Face & Skin, published in Appl Mater Today (2023) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Appl Mater Today (2023)
Reported sample size
—
Source database
Europe PMC
PMID
40822708
PMCID
PMC12352411
DOI
10.1016/j.apmt.2023.101834
Citations
4

Abstract (original English)

Cellular membrane-derived vesicles (CMVs) have recently attracted attention as a drug delivery system (DDS) because CMVs offer unique advantages, including nanosized particles, superior transcellular cross-communication, excellent biocompatibility, and active targeting ability. However, some challenges remain in the design and production of CMVs, such as their low yield, chemical and mechanical instability, and difficulties in functionalizing membrane surfaces. In this paper, we introduce three strategies to overcome the limitation of CMVs. First, hybrid vesicles combined CMVs from cellular membranes with synthetic liposomes (SLs) offer new engineering solutions to tackle such issues. The membrane fusion of SLs and CMVs can increase their production yield and stability while allowing for the presentation of surface proteins from donor cells. Additional compounds, such as targeted ligands and imaging agents, can be easily integrated into CMVs by using functionalized SLs. Second, core/shell nanostructures composed of synthetic nanoparticles as cores and cell membrane structures as shells can offer unique advantages for improving the stability and preservation of the inherent capabilities of the various nanoparticles in these core/shell nanostructures. Lastly, CMV/scaffold complexes are also a pronounced approach for DDSs because the scaffold structures help CMVs or loaded therape

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research